Century Therapeutics Inc. (IPSC)
Century Therapeutics Statistics
Share Statistics
Century Therapeutics has 85.03M shares outstanding. The number of shares has increased by 31.18% in one year.
| Shares Outstanding | 85.03M |
| Shares Change (YoY) | 31.18% |
| Shares Change (QoQ) | 0.37% |
| Owned by Institutions (%) | 46.81% |
| Shares Floating | 36.09M |
| Failed to Deliver (FTD) Shares | 527 |
| FTD / Avg. Volume | 0.09% |
Short Selling Information
The latest short interest is 3.02M, so 3.56% of the outstanding shares have been sold short.
| Short Interest | 3.02M |
| Short % of Shares Out | 3.56% |
| Short % of Float | 8.69% |
| Short Ratio (days to cover) | 5.01 |
Valuation Ratios
The PE ratio is -1.44 and the forward PE ratio is -0.46. Century Therapeutics's PEG ratio is -1.09.
| PE Ratio | -1.44 |
| Forward PE | -0.46 |
| PS Ratio | 88.11 |
| Forward PS | 0.4 |
| PB Ratio | 1.07 |
| P/FCF Ratio | -1.93 |
| PEG Ratio | -1.09 |
Enterprise Valuation
Century Therapeutics Inc. has an Enterprise Value (EV) of 197.77M.
| EV / Earnings | -1.45 |
| EV / Sales | 88.49 |
| EV / EBITDA | -1.63 |
| EV / EBIT | -1.35 |
| EV / FCF | -1.94 |
Financial Position
The company has a current ratio of 9.92, with a Debt / Equity ratio of 0.26.
| Current Ratio | 9.92 |
| Quick Ratio | 9.92 |
| Debt / Equity | 0.26 |
| Total Debt / Capitalization | 20.68 |
| Cash Flow / Debt | -1.83 |
| Interest Coverage | -271.38 |
Financial Efficiency
Return on equity (ROE) is -0.74% and return on capital (ROIC) is -63.79%.
| Return on Equity (ROE) | -0.74% |
| Return on Assets (ROA) | -0.38% |
| Return on Capital (ROIC) | -63.79% |
| Revenue Per Employee | 14.7K |
| Profits Per Employee | -899.16K |
| Employee Count | 152 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 1.88M |
| Effective Tax Rate | -0.01 |
Stock Price Statistics
The stock price has increased by -83.08% in the last 52 weeks. The beta is 1.74, so Century Therapeutics's price volatility has been higher than the market average.
| Beta | 1.74 |
| 52-Week Price Change | -83.08% |
| 50-Day Moving Average | 0.89 |
| 200-Day Moving Average | 1.72 |
| Relative Strength Index (RSI) | 27.88 |
| Average Volume (20 Days) | 581.13K |
Income Statement
In the last 12 months, Century Therapeutics had revenue of 2.23M and earned -136.67M in profits. Earnings per share was -2.3.
| Revenue | 2.23M |
| Gross Profit | -10.81M |
| Operating Income | -146.55M |
| Net Income | -136.67M |
| EBITDA | -121.21M |
| EBIT | -146.55M |
| Earnings Per Share (EPS) | -2.3 |
Balance Sheet
The company has 47.32M in cash and 48.17M in debt, giving a net cash position of -847K.
| Cash & Cash Equivalents | 47.32M |
| Total Debt | 48.17M |
| Net Cash | -847K |
| Retained Earnings | -655.77M |
| Total Assets | 388.62M |
| Working Capital | 186.19M |
Cash Flow
In the last 12 months, operating cash flow was -88.35M and capital expenditures -13.74M, giving a free cash flow of -102.08M.
| Operating Cash Flow | -88.35M |
| Capital Expenditures | -13.74M |
| Free Cash Flow | -102.08M |
| FCF Per Share | -1.72 |
Margins
Gross margin is -483.62%, with operating and profit margins of -6.56K% and -6.12K%.
| Gross Margin | -483.62% |
| Operating Margin | -6.56K% |
| Pretax Margin | -6.03K% |
| Profit Margin | -6.12K% |
| EBITDA Margin | -5.42K% |
| EBIT Margin | -6.56K% |
| FCF Margin | -4.57K% |
Dividends & Yields
IPSC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -343.28% |
| FCF Yield | -178.9% |
Analyst Forecast
The average price target for IPSC is $8, which is 1094% higher than the current price. The consensus rating is "Buy".
| Price Target | $8 |
| Price Target Difference | 1094% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -3.03 |
| Piotroski F-Score | 4 |